文献速递妇科肿瘤

尼拉帕利单药用于卵巢癌后线治疗(QUADRA):一项多中心、开放标签、单臂、2期试验

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-04-01

QUADRA研究评估尼拉帕利单药作为第四线或更后线治疗复发高级别浆液性卵巢癌等的疗效与安全性。主要疗效人群中47例可评估患者有13例(28%)达到总体缓解(95%CI 15.6-42.6;单侧p=0.00053)。常见药物相关≥3级不良事件为贫血(24%)和血小板减少(21%)。

要点

  • 主要疗效人群(HRD阳性、铂敏感、既往3或4线治疗)中28%达到总体缓解。
  • 常见药物相关≥3级不良事件为贫血(24%)和血小板减少(21%)。
  • 作者认为数据支持将PARP抑制剂适应证扩展至BRCA突变以外的HRD阳性卵巢癌患者。

核心结论

  • 在经重度治疗的卵巢癌女性中观察到尼拉帕利具有临床相关活性,尤其是HRD阳性铂敏感疾病患者,包括BRCA野生型患者。
  • 未发现新的安全性信号。
  • 作者认为数据支持将聚(ADP-核糖)聚合酶抑制剂治疗适应证扩展至BRCA突变以外的HRD阳性卵巢癌患者。

研究设计与样本

  • QUADRA为多中心、开放标签、单臂、2期研究,在美国和加拿大进行,56个中心筛选患者(50个中心至少治疗1例患者)。
  • 入组成人(≥18岁)复发高级别浆液性(2或3级)上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,既往接受过3线或以上化疗。
  • 患者口服尼拉帕利300 mg每日一次持续给药,从第1天开始,此后每周期(28天)直至疾病进展。
  • 主要疗效人群为HRD阳性肿瘤(包括BRCA突变和无BRCA突变)、对末次铂类治疗敏感、既往接受过3或4线抗癌治疗的患者。
  • 2015年4月1日至2017年11月1日筛选729例,入组463例并开始尼拉帕利治疗;数据库锁定时(2018年4月11日)入组已关闭、研究进行中,21例仍在治疗。

主要发现

  • 患者既往接受治疗线数中位为4线(IQR 3-5),总生存随访中位为12.2个月(IQR 3.7-22.1)。
  • 463例患者中151例(33%)对末次铂类治疗耐药,161例(35%)难治。
  • 主要疗效人群47例中13例(28%)达到研究者评估的确认总体缓解(RECIST),95%CI 15.6-42.6,单侧p=0.00053。
  • 最常见的药物相关≥3级治疗中出现的不良事件为贫血(463例中113例[24%])和血小板减少(463例中95例[21%])。
  • 最常见的治疗中出现的严重不良事件为小肠梗阻(463例中34例[7%])、血小板减少(463例中34例[7%])和呕吐(463例中27例[6%]);1例胃出血死亡被认为与治疗相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5-9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy. METHODS: QUADRA was a multicentre, open-label, single-arm, phase 2 study that evaluated the safety and activity of niraparib in adult patients (≥18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had been treated with three or more previous chemotherapy regimens. The study was done in the USA and Canada, and 56 sites screened patients (50 sites treated at least one patient). Patients received oral niraparib 300 mg once daily continuously, beginning on day 1 and every cycle (28 days) thereafter until disease progression. The primary objective was the proportion of patients achieving an investigator-assessed confirmed overall response in patients with homologous recombination deficiency (HRD)-positive tumours (including patients with BRCA and without BRCA mutations) sensitive to their last platinum-based therapy who had received three or four previous anticancer therapy regimens (primary efficacy population). Efficacy analyses were additionally done in all dosed patients with measurable disease at baseline. FINDINGS: Between April 1, 2015 and Nov 1, 2017, we screened 729 patients for eligibility and enrolled 463 patients, who were initiated on niraparib therapy. At the time of database lock (April 11, 2018), enrolment had closed and the study was ongoing, with 21 patients still on treatment. Patients had received a median of four (IQR 3-5) previous lines of therapy, and the median follow-up for overall survival was 12·2 months (IQR 3·7-22·1). 151 (33%) of 463 patients were resistant and 161 (35%) of 463 patients were refractory to the last administered platinum therapy. 13 (28%) of 47 patients in the primary efficacy population achieved an overall response according to RECIST (95% CI 15·6-42·6; one-sided p=0·00053). The most common drug-related grade 3 or worse treatment-emergent adverse events were anaemia (113 [24%] of 463 patients) and thrombocytopenia (95 [21%] of 463 patients). The most common treatment-emergent serious adverse events were small intestinal obstruction (34 [7%] of 463 patients), thrombocytopenia (34 [7%] of 463 patients), and vomiting (27 [6%] of 463 patients). One death due to gastric haemorrhage was considered treatment related. INTERPRETATION: We observed clinically relevant activity of niraparib among women with heavily pretreated ovarian cancer, especially in patients with HRD-positive platinum-sensitive disease, which includes not only patients with a BRCA mutation but also a population with BRCA wild-type disease. We identified no new safety signals. Our data support expansion of the treatment indication for poly(ADP-ribose) polymerase inhibitors to include patients with HRD-positive ovarian cancer beyond those with BRCA mutations. FUNDING: Tesaro.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019. PMID: 30948273. doi:10.1016/S1470-2045(19)30029-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。